Prescription medicine
Calaspargase Brand names: Asparlas
Calaspargase (Asparlas) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the calaspargase FDA label on DailyMed (effective October 8, 2024); every calaspargase label on DailyMed.
Highlights of the record
FDA label of October 8, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageASPARLAS is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
Forms and strengths
Injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 745 through July 30, 2026
What is calaspargase used for?
From the label: indications and usageASPARLAS is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years. ( 1.1 ) 1.1 Acute Lymphoblastic Leukemia ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
Conditions named in the indications of calaspargase's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Asparagine-specific Enzyme.
Source: FDA drug label (asparlas), Servier Pharmaceuticals LLC, effective October 8, 2024 (SPL set 6585bd0d-bd78-4341-9e87-0f7664821f05), via openFDA; the full label on DailyMed
Is there a generic for calaspargase (Asparlas)?
No generic calaspargase is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the calaspargase label say about other medicines?
The calaspargase label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Epinephrine | warnings and precautions | Because of the risk of serious allergic reactions (e.g., life-threatening anaphylaxis), administer ASPARLAS in a clinical setting with resuscitation equipment and other agents necessary to treat anaphylaxis (e.g., epinephrine, oxygen, intravenous steroids, antihistamines) [see Dosage and Administration (2.4) ] and … |
Source: FDA drug label (asparlas), Servier Pharmaceuticals LLC, effective October 8, 2024 (SPL set 6585bd0d-bd78-4341-9e87-0f7664821f05), via openFDA; the full label on DailyMed
What do FAERS reports show for calaspargase?
The FDA Adverse Event Reporting System holds 745 reports that list calaspargase among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 54 are coded as a death and 303 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as calaspargase?
36 other medicines are given the same way (intravenous) and in the same FDA class as calaspargase or labeled mainly for the same use (leukemia, lymphoma and myeloma), the same class first. Leukemia, lymphoma and myeloma lists all 98 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Cyclophosphamide | Leukemia, lymphoma and myeloma | 15 labelers | n/a | No current entry |
| Doxorubicin | Leukemia, lymphoma and myeloma | 16 labelers | n/a | No current entry |
| Bortezomib | Leukemia, lymphoma and myeloma | 22 labelers | n/a | No current entry |
| Arsenic trioxide | Leukemia, lymphoma and myeloma | 16 labelers | n/a | A presentation being discontinued |
| Bendamustine | Leukemia, lymphoma and myeloma | 4 labelers | n/a | A presentation being discontinued |
| Nelarabine | Leukemia, lymphoma and myeloma | 12 labelers | n/a | No current entry |
| Idarubicin | Leukemia, lymphoma and myeloma | 2 labelers | n/a | No current entry |
| Clofarabine | Leukemia, lymphoma and myeloma | 9 labelers | n/a | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Other asparagine-specific enzymes
- the pharmacologic class, with prices and generics
- Calaspargase side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other